Treatments for obesity

Autor: DJ Goldstein, ME Trautmann

Publikováno v: Emerging Drugs. 2:1-28

Summary Obesity is a chronic condition of very high prevalence. It is associated with increased morbidity and mortality because of obesity-related conditions, such as non-insulin dependent diabetes mellitus (NIDDM), hypertension, and hyperlipidaemia.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c81239223c772183d86f2b1a5eb7c58
https://doi.org/10.1517/14728214.2.1.1

Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.

Autor: Hompesch M; Clinical Investigation, ProSciento Inc, Chula Vista, California, USA Marcus.Hompesch@prosciento.com., Kang J; Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea., Han O; Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea., Trautmann ME; Clinical Investigation, ProSciento Inc, Chula Vista, California, USA., Sorli CH; Sanofi, Bridgewater, New Jersey, USA., Ogbaa I; Sanofi, Bridgewater, New Jersey, USA., Stewart J; Sanofi Canada, Laval, Quebec, Canada., Morrow L; Clinical Investigation, ProSciento Inc, Chula Vista, California, USA.

Publikováno v: BMJ open diabetes research & care [BMJ Open Diabetes Res Care] 2021 Jun; Vol. 9 (1).

Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.

Autor: Del Prato S; Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy., Kang J; Hanmi Pharmaceutical Co., Ltd, Seoul, South Korea., Trautmann ME; ProSciento, Chula Vista, California., Stewart J; Sanofi Canada, Laval, Quebec, Canada., Sorli CH; Sanofi, Bridgewater, New Jersey., Derwahl M; IKFE Berlin GmbH Institute for Clinical Research and Development, Berlin, Germany., Soto A; Servicio de Endocrinología y Nutrición, Hospital de A Coruña, La Coruña, Spain., Yoon KH; The Catholic University of Korea, Seoul, South Korea.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Jul; Vol. 22 (7), pp. 1176-1186. Date of Electronic Publication: 2020 Apr 06.

Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.

Autor: Rosenstock J; Dallas Diabetes Research Center at Medical City, Dallas, TX juliorosenstock@dallasdiabetes.com., Sorli CH; Sanofi, Bridgewater, NJ., Trautmann ME; ProSciento, Chula Vista, CA., Morales C; Day Hospital & Diabetes Research Unit, Clinical Management Unit Endocrinology and Nutrition, Virgen Macarena University Hospital, Seville, Spain., Wendisch U; Group Practice in Internal Medicine and Diabetology, Hamburg, Germany., Dailey G; Scripps Clinic, John R. Anderson V Medical Pavilion, La Jolla, CA., Hompesch M; ProSciento, Chula Vista, CA., Choi IY; Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea., Kang J; Hanmi Pharmaceutical Co., Ltd., Seoul, South Korea., Stewart J; Sanofi Canada, Laval, Quebec, Canada., Yoon KH; The Catholic University of Korea, Seoul, South Korea.

Publikováno v: Diabetes care [Diabetes Care] 2019 Sep; Vol. 42 (9), pp. 1733-1741. Date of Electronic Publication: 2019 Jul 18.

Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.

Autor: Trautmann ME; Diabetes Research, Hamburg, Germany., Vora J; Diabetes and Endocrinology, Royal Liverpool University Hospital, Liverpool, UK.; AstraZeneca, Cambridge, UK.

Publikováno v: Diabetic medicine : a journal of the British Diabetic Association [Diabet Med] 2018 Jun; Vol. 35 (6), pp. 694-706. Date of Electronic Publication: 2018 Mar 24.